Petition: Create a publicly owned manufacturer for off-patent, generic drugs in the UK
Price gouging is where companies substantially raise prices above costs of production and investment, often due to a lack of competition. Generic drugs are non-brand, off-patent medicines. They benefit from a legal loophole, facing much less price regulation than branded drugs.
Did you know that….
Hydrocortisone is an essential drug according to the World Health Organisation?
Auden McKenzie increased the price of this generic drug from £1.07 to £147.50 for 1 month’s supply between 2008 and 2017?
The NHS was forced to pay an extra £60 million per year until 2017!
A study, funded by the NIHR (the research arm of the NHS), required a modest investment of approximately £100,000 which contributed to a reducing trend in hydrocortisone prices, from over £147.50pcm to £3.55pcm between 2017 and March 2021.
Want to know more?
Recent Blog Posts
New report highlights access gap for innovative medicines
The CAH Support Group recently provided input into a new Medicines Australia report about access to innovative medicines in Australia. The report, now published, warns that Australian patients are missing access to some innovative medicines available in comparable...
Help Shape New UK Sick Day Guidance for Young People with Adrenal Insufficiency
Young people with adrenal insufficiency (including CAH and Addison's disease) and parents/carers are being invited to help shape new UK-wide resources on sick day rules and emergency management. The project is being led by Edge Hill University in partnership with the...
Article: Adult Quality of Life with CAH
A new study published in Endocrine Connections explores the lived experiences of adults with congenital adrenal hyperplasia (CAH) and the wide-ranging impact the condition can have on quality of life. Through in-depth interviews with adults living with CAH as well as...